Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Frontiers in Immunology|June 6, 2022
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus FoliaceusMaud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, et al.The Journal of Investigative Dermatology|June 18, 2026
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigusMaud Maho-Vaillant, Alexis Lefebvre, Marie-Laure Golinski, et al.Biomedicines|October 23, 2021
Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid TreatmentMarie Petit, Marie-Laure Walet-Balieu, Damien Schapman, et al.The Journal of Investigative Dermatology|March 26, 2021
Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in PemphigusMaud Maho-Vaillant, Corine Perals, Marie-Laure Golinski, et al.Biomedicines|July 27, 2022
IgG N-Glycosylation from Patients with Pemphigus Treated with RituximabGuillaume Font, Marie-Laure Walet-Balieu, Marie Petit, et al.Experimental Eye Research|July 21, 2026
Cellular and cytokine responses of corneal fibroblasts exposed to keratopigmentation inks invitroArnaud Gaulier, Maud Maho-Vaillant, Magalie Benard, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 1, 2014
Human regulatory B cells combine phenotypic and genetic hallmarks with a distinct differentiation fateWenyu Lin, Daniela Cerny, Edmond Chua, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 27, 2026
Tocilizumab for severe and refractory mucous membrane pemphigoidBillal Tedbirt, Maud Maho-Vaillant, Julie Gueudry, et al.Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.Pageof 3